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Establishing prevalence in rare
neuromuscular diseases
A lesson from congenital myopathies
Congenital myopathies (CMs) are a heterogeneous
group of early-onset muscle disorders with weakness,
distinct histopathologic features, and normal to
slightly elevated creatine kinase (CK).1 The age at
onset and clinical severity can be variable, ranging
from severely affected at birth to a milder later-onset
disease.2 Cardiac involvement has been reported.3,4
CMs are generally considered nonprogressive disor-
ders. Three main categories are recognized within
the classical CMs based on their typical histopathol-
ogy: nemaline myopathy (NM), core myopathy, and
centronuclear myopathy (CNM). Inheritance in
CMs may be dominant, recessive, or X-linked.
Greater than 25 unique genetic causes of CM have
been identified and different types of mutations
within the same gene (e.g., deletions, duplications,
missense, nonsense, splice-site, and frameshift mu-
tations) have been identified, as well as de novo
dominant mutations.5
In this issue of Neurology® Genetics, Witting et al.6
report a comprehensive analysis of the prevalence,
genotype, and phenotype of CM in patients 5 years
and older in Denmark. The study was conducted at
the Copenhagen neuromuscular center, Rigshospitalet,
Denmark, in collaboration with the Danish National
Rehabilitation Center for Neuromuscular Diseases.
After identifying all registered Danish patients with
a diagnosis of CM aged older than 5 years, compre-
hensive clinical, histopathologic, and genetic investiga-
tions were performed. This approach allowed for
a unique prospective assessment of this patient group
that has not been studied previously in CMs.
The study found that the prevalence of CM in
Danish patients older than 5 years (age range 5–69
years with a mean of ;28 years) was 2:100,000;
significantly lower than previous studies that esti-
mated the prevalence at ;4:100,000.7,8 This may
be due to the exclusion of pediatric patients who have
succumbed to their illness prior to age 5. This limi-
tation, although acknowledged by the authors, under-
represents an entire group of early-onset CMs with
high mortality in the first few years of life. This may
also account for the lower prevalence of MTM1
mutations–carrying patients in this study.9,10
The prevalence did not include patients who phe-
notypically and pathologically fulfilled criteria for
CM yet were found to have a genetic etiology consid-
ered not to be associated with CM. Whether this
patient group was included in other studies is not
entirely clear. However, 10 patients had mutations
in DES, COLVI, COLXII, DOK7, and RAPSN.
These patients are interesting because some had path-
ologic features of NM, core myopathy, and CNM.
Notably, DES mutations were identified in one
patient with NM and another with core myopathy.
Whether these genes explain undiagnosed causes of
CM in the global patient population remains to be
determined. Notably, DES and genes associated with
congenital myasthenic syndrome are not routinely
included in CM gene panels. Therefore, neurologists
should consider these etiologies in patients with CM
and an unknown genetic cause.
A genetic etiology was reached in 56% of Danish
CM patients. This is somewhat lower than in other
similar studies in which a genetic cause was found
in 67%–79% of patients.11,12 This may relate to the
inclusion of patients without distinctive features on
biopsy, but a phenotype consistent with CM. For
example, in patients with histopathologic features
consistent with NM, CNM, or core myopathy,
a genetic diagnosis was identified in 83% of patients.
By contrast, in patients with unspecific histopatho-
logic features, the genetic diagnosis was achieved in
only 21% of patients.
Another unique aspect of this study was the inclu-
sion of patients with CM regardless of age. Indeed,
the oldest patient was a 69-year-old woman with
a DNM2 mutation. Although difficult to ascertain
from the small cohort size, in general, older and youn-
ger patients with CM demonstrated a consistent phe-
notypic pattern of weakness depending on their gene
mutation. Moreover, older patients with CM
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continued being active in their education or work life.
This supports the prevailing theory that CM is a non-
progressive disorder.
Studies such as that performed by Witting et al.,
which define the prevalence and genetic heterogene-
ity of a defined patient population, are the next step
in neuromuscular patient care. How the composition
of Danish CM patients relates to other countries or
even individual academic centers remains to be deter-
mined. Research initiatives focused on the identifica-
tion of novel genetic etiologies are important, but
reporting the genetic makeup of existing patient
populations is absolutely essential, as we enter
a new and exciting era of personalized neuromuscular
therapeutics.
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